Literature DB >> 24081203

Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method.

Marjolijn J P van Wanrooy1, Riaaz N Santoe, Kim C M van der Elst, Carli M Wilmer, Kai van Hateren, A Mireille A Wessels, Ben Greijdanus, Jan-Willem C Alffenaar, Donald R A Uges.   

Abstract

INTRODUCTION: Echinocandins are a valuable addition for the treatment of invasive fungal infections, as they are efficacious, demonstrate low toxicity, and have limited drug-drug interactions. In specific clinical situations when altered pharmacokinetics can be expected or dosing guidelines are conflicting, it may be useful to measure concentrations. For this purpose, a liquid chromatography tandem mass-spectrometric method to measure anidulafungin and caspofungin in ethylenediaminetetraacetic acid plasma was developed.
METHODS: The method was developed on a Thermo Fisher TSQ Quantum LC-MS/MS. For separation, a BetaBasic C4 (100 mm × 3.0 mm; 5 μm) analytical column was used. Sample preparation consisted of protein precipitation directly in the autosampler vial. The internal standard aculeacin A is structurally related, not used in humans, and commercially available. The method was validated according to the guidelines for bioanalytical method validation of the Food and Drug Administration.
RESULTS: The method was accurate (bias ranging from -3.0% to 1.9%) and precise (within-run and between-run coefficients of variation of 2.2% to 7.7% and 1.6% to 9.0%, respectively). All calibration curves were linear over a range of 0.5-10.0 mg/L for anidulafungin and 0.1-20.0 mg/L for caspofungin, and if necessary, samples can be diluted 10-fold. The samples were stable for 3 freeze-thaw cycles, with a bias ranging from 0.6% to 11%. The maximum bias from the worst storage condition, 72 hours at room temperature, was -14.7%. In patient samples, anidulafungin peak concentrations ranged from 2.8 to 8.6 mg/L (n = 20) and trough concentrations ranged from 1.0 to 4.7 mg/L (n = 79). The measured caspofungin concentrations ranged from 1.9 to 7.3 mg/L (n = 20).
CONCLUSIONS: The method developed has a straightforward sample preparation and uses a structural analog as the internal standard. This method has been applied successfully for the measurement of anidulafungin and caspofungin concentrations in patient samples, both for clinical practice and for research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081203     DOI: 10.1097/FTD.0b013e31829591a7

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Low Caspofungin Exposure in Patients in Intensive Care Units.

Authors:  Kim C M van der Elst; Anette Veringa; Jan G Zijlstra; Albertus Beishuizen; Rob Klont; Petra Brummelhuis-Visser; Donald R A Uges; Daan J Touw; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Limited-sampling strategies for anidulafungin in critically ill patients.

Authors:  Marjolijn J P van Wanrooy; Johannes H Proost; Michael G G Rodgers; Jan G Zijlstra; Donald R A Uges; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

3.  Low but sufficient anidulafungin exposure in critically ill patients.

Authors:  Marjolijn J P van Wanrooy; Michael G G Rodgers; Donald R A Uges; Jan P Arends; Jan G Zijlstra; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

4.  Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients.

Authors:  Michael Neely; Jan-Willem Alffenaar; Anne-Grete Märtson; Kim C M van der Elst; Anette Veringa; Jan G Zijlstra; Albertus Beishuizen; Tjip S van der Werf; Jos G W Kosterink
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 5.  Invasive Candidiasis in the Elderly: Considerations for Drug Therapy.

Authors:  B G J Dekkers; A Veringa; D J E Marriott; J M Boonstra; K C M van der Elst; F F Doukas; A J McLachlan; Jan-Willem C Alffenaar
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.